Glenmark Shapes Immuno-Oncology Play With Early-Stage APC Asset
Glenmark Pharmaceuticals has in-licensed a small molecule oncology compound from APC Therapeutics Inc, expanding its interests in the promising immuno-oncology space. One of the founders of APC has even joined the Indian firm.
You may also be interested in...
Recently approved Bavencio will be paired with experimental MNK1/2 inhibitor in microsatellite-stable colorectal cancer. CRO Parexel to go private, AbbVie teams with Principia in immunology R&D and more.
Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?
FDA officials outline the impact of using alternative tools to assess manufacturing facilities amid COVID-19 and share key experiences around these, including with remote interactive evaluations.